liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Show others and affiliations
2015 (English)In: Journal of Clinical Investigation, ISSN 0021-9738, E-ISSN 1558-8238, Vol. 125, no 12, 4612-4624 p.Article in journal (Refereed) PublishedText
Abstract [en]

Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1-negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.

Place, publisher, year, edition, pages
AMER SOC CLINICAL INVESTIGATION INC , 2015. Vol. 125, no 12, 4612-4624 p.
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-123783DOI: 10.1172/JCI81031ISI: 000365831300026PubMedID: 26551678OAI: oai:DiVA.org:liu-123783DiVA: diva2:892947
Note

Funding Agencies|Swedish Research Council; Ragnar Soderberg Foundation; Karolinska Institutet; Borje Dahlin Foundation; Swedish Rheumatism Association; King Gustaf V 80-year Foundation; Stockholm County Council; Karolinska Institutet on medical training and clinical research (ALF); Swedish Strategic Foundation (PRIMI); Torsten Soderberg Foundation

Available from: 2016-01-11 Created: 2016-01-11 Last updated: 2016-01-11

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Danielsson, Olof
By organisation
Division of Neuro and Inflammation ScienceFaculty of Medicine and Health Sciences
In the same journal
Journal of Clinical Investigation
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 90 hits
ReferencesLink to record
Permanent link

Direct link